High PCSK9 expression in baseline tumor tissue was associated with reduced efficacy of anti-PD-1 immunotherapy in advanced NSCLC patients. The PCSK9 inhibitor combining with the anti-CD137 agonist not only enhanced the recruitment of CD8+ T cells but also reduced Tregs. Here, PDCD1 is linked to neoplasm.